Nippon Life Insurance Co. decreased its position in shares of Humana Inc (NYSE:HUM) by 7.4% during the first quarter, Holdings Channel reports. The firm owned 7,238 shares of the insurance provider’s stock after selling 577 shares during the period. Nippon Life Insurance Co.’s holdings in Humana were worth $1,492,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hermes Investment Management Ltd. raised its position in Humana by 0.9% in the first quarter. Hermes Investment Management Ltd. now owns 78,911 shares of the insurance provider’s stock worth $16,267,000 after buying an additional 700 shares during the period. State of Alaska Department of Revenue bought a new position in Humana during the first quarter worth $342,000. Columbus Circle Investors raised its position in Humana by 97.4% in the first quarter. Columbus Circle Investors now owns 13,623 shares of the insurance provider’s stock worth $2,808,000 after buying an additional 6,722 shares during the period. Granite Investment Advisors LLC raised its position in Humana by 12.1% in the first quarter. Granite Investment Advisors LLC now owns 2,410 shares of the insurance provider’s stock worth $497,000 after buying an additional 260 shares during the period. Finally, Quantitative Systematic Strategies LLC bought a new position in Humana during the first quarter worth $375,000. 93.00% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Humana Inc (NYSE:HUM) traded down 0.27% during trading on Friday, hitting $213.67. The stock had a trading volume of 1,710,744 shares. Humana Inc has a 52-week low of $150.00 and a 52-week high of $220.49. The company’s 50 day moving average is $212.85 and its 200 day moving average is $199.93. The firm has a market cap of $31.91 billion, a PE ratio of 52.50 and a beta of 0.91.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 8th. The insurance provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.05 by $0.04. Humana had a net margin of 1.09% and a return on equity of 13.09%. The business had revenue of $12.88 billion for the quarter, compared to analyst estimates of $13.55 billion. During the same period in the prior year, the company posted $1.45 EPS. The company’s revenue for the quarter was up .7% on a year-over-year basis. Equities research analysts forecast that Humana Inc will post $10.94 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.75%. The ex-dividend date is Wednesday, June 28th. Humana’s payout ratio is currently 29.59%.

ILLEGAL ACTIVITY WARNING: “Nippon Life Insurance Co. Has $1.492 Million Position in Humana Inc (HUM)” was originally posted by Financial Market News and is owned by of Financial Market News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.financial-market-news.com/2017/04/21/nippon-life-insurance-co-has-1-492-million-position-in-humana-inc-hum.html.

A number of research firms recently weighed in on HUM. Jefferies Group LLC lowered Humana from a “buy” rating to a “hold” rating and set a $221.00 price objective for the company. in a research report on Friday. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $237.00 price objective for the company in a research report on Tuesday. Deutsche Bank AG began coverage on Humana in a research report on Wednesday, April 5th. They set a “hold” rating and a $216.00 price objective for the company. CIBC reaffirmed an “outperform” rating on shares of Humana in a research report on Thursday, March 30th. Finally, Oppenheimer Holdings Inc. began coverage on Humana in a research report on Thursday, March 30th. They set an “outperform” rating and a $236.00 price objective for the company. Nine equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Humana currently has a consensus rating of “Buy” and an average price target of $210.56.

In other news, SVP Jody L. Bilney sold 4,348 shares of the stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $213.80, for a total transaction of $929,602.40. Following the sale, the senior vice president now directly owns 13,578 shares of the company’s stock, valued at approximately $2,902,976.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Brian P. Leclaire sold 26,894 shares of the stock in a transaction dated Wednesday, February 22nd. The stock was sold at an average price of $205.24, for a total transaction of $5,519,724.56. Following the sale, the senior vice president now directly owns 25,734 shares in the company, valued at $5,281,646.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 319,632 shares of company stock worth $65,897,204. Corporate insiders own 0.50% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

5 Day Chart for NYSE:HUM

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.